Genitourinary Cancers | Clinical

ICIs Show Improved Survival Over Targeted Therapies in Advanced Non–Clear Cell RCC

April 20, 2021

As a class, immune checkpoint inhibitor-based regimens outshine select targeted therapies in overall survival in patients with metastatic non–clear cell renal cell carcinoma.

Immuno-Oncology/TKI Combinations Take the Lead in Frontline RCC Therapy

April 18, 2021

Although curing advanced RCC is an admirable goal, there are many treatment options available on the horizon that result in substantial improvements in long-term outcomes.

NCCN Guidelines for RCC Add Frontline Lenvatinib/Pembrolizumab as Preferred Treatment Option

April 17, 2021

Recent updates to the National Comprehensive Cancer Network’s guidelines for renal cell carcinoma reflect quick integration of new agents and combination regimens to provide patients with RCC with more treatment options and the most up-to-date options.

Men With High Genetic Risk of Lethal Prostate Cancer May Lower Their Risk With a Healthier Lifestyle

April 10, 2021

According to new research presented during the virtual AACR Annual Meeting 2021, the likelihood of developing metastatic disease or dying of prostate cancer among men with high genetic risk was lowered in men who maintained a healthy lifestyle.

Similar Outcomes of Multiple Hormonal Agents Give Oncologists Novel Treatment Options for Patients With nmCRPC

April 02, 2021

Alicia K. Morgans, MD, MPH, associate professor of Medicine, Feinberg School of Medicine, Northwestern University, reviewed the clinical trial results for multiple hormonal therapies intended to treat prostate cancer. She explained that many of them show similar outcomes.

What’s Next for Advanced RCC?

March 29, 2021

A look toward the future treatment of advanced renal cell carcinoma.

Considerations for Len-Pembro in Clinical Practice

March 29, 2021

Expert perspectives on the clinical utility of lenvatinib plus pembrolizumab as a frontline combination for advanced renal cell carcinoma.

Dosing Strategies to Maximize Efficacy in RCC

March 29, 2021

Robert J. Motzer, MD, discusses dosing strategies to mediate toxicities and maximize efficacy from the frontline combination of lenvatinib plus pembrolizumab for renal cell carcinoma.

Are Combinations the Answer in Metastatic RCC?

March 29, 2021

Robert J. Motzer, MD, provides perspective on recent data from the phase 3 CLEAR trial (Study 307)/KEYNOTE-581 for advanced renal cell carcinoma.

Strong Efficacy and Favorable Safety From CLEAR for RCC

March 29, 2021

A comprehensive review of the efficacy and safety data from the phase 3 CLEAR trial (Study 307/KEYNOTE-581) for the frontline treatment of advanced renal cell carcinoma.